Leading Through Innovation

Caring with Compassion

At Julphar, our mission is simple — to provide a better quality of life for the entire family by delivering best in class solutions and real value

Happy Family

Our Products

We produce a wide range of
medicines, vaccines and consumer healthcare products for conditions ranging from headaches to heart disease

Our Facilities

Our state-of-the-art facilities have comprehensive manufacturing capabilities and meet the highest standards of quality and safety 

Latest News

Gulf Pharmaceutical Industries (Julphar) Reports Financial Results for Q2 2020
2020-08-16
- Julphar announces 90% increase in sales in comparison to Q2 2019 - Strong result improvement with 6% EBITDA margin in Q2 2020

Latest News

Gulf Pharmaceutical Industries (Julphar) rights issue oversubscribed by 2.3 times
2020-07-15
- Julphar launched AED 500 million rights issue at an offer price of AED 1 per share on 29th June 2020 - Total bids received from existing rightsholders stood at AED 1.14 billion on application which closed on 12th July 2020

Latest News

Julphar resumes sales of products in Bahrain and Kuwait
2020-06-09
After an inspection of Julphar facilities, the Gulf Health Council and the Pharmaceutical & Herbal Medicine Registration & Quality Control Admin, Ministry of Health, State of Kuwait has lifted the temporary suspension on the export of Julphar products to Bahrain and Kuwait

Latest News

Gulf Pharmaceutical Industries (Julphar) launches AED 500 million rights issue
2020-06-01
- Rights issue is part of Julphar's capital restructuring to improve the capital base and debt profile. - The company will offer 500 million new shares with a nominal value of AED 1. Ras Al Khaimah, UAE; June 1, 2020: Gulf Pharmaceutical Industries PSC (Julphar), one of the largest pharmaceutical manufacturers in the Middle East and Africa, announced today the launch of its AED 500 million rights issue as the company progresses on its ambitious turnaround plan. The rights issue is set to improve the company’s capital position and debt profile and will provide the financial foundation for the successful implementation of the company’s medium-term growth strategy.

Latest News

Julphar resumes sales of products in KSA
2020-04-30
After an inspection of Julphar facilities, Saudi Food and Drug Authority has lifted the temporary suspension on the export of Julphar products to Saudi Arabia

Latest News

Julphar’s Shareholders Approve Capital Restructuring
2020-04-12
Capital reduction, followed by an up to AED 500 million rights issue, will extinguish accumulated losses and is part of a comprehensive transformation programme
This website intends to use cookies to improve the site and your experience. By continuing to browse the site you are agreeing to accept our use of cookies. If you require further information and/or do not wish to have cookies placed when using the site, refer to our Cookie Policy.